Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
Cash Flows From Operating Activities | |||||
Net Income | 6,602,621 | 6,086,785 | 7,007,510 | 8,202,192 | 6,726,709 |
Depreciation Amortization | 2,853,507 | 2,655,625 | N/A | 3,018,684 | 2,980,285 |
Accounts receivable | -987,657 | -195,430 | N/A | -287,616 | -40,861 |
Accounts payable and accrued liabilities | -18,659 | 611,029 | N/A | 288,900 | 335,825 |
Other Working Capital | -1,064,778 | 333,963 | N/A | 3,150,936 | 453,300 |
Other Operating Activity | 1,033,680 | -335,200 | 3,927,280 | -3,534,856 | -214,517 |
Operating Cash Flow | $8,418,715 | $9,156,771 | $10,934,790 | $10,838,240 | $10,240,740 |
Cash Flows From Investing Activities | |||||
Change In Deposits | 2,215,386 | 118,742 | 79,756 | 3,668,388 | -240,057 |
PPE Investments | -1,599,655 | -1,233,189 | -1,414,978 | -1,486,872 | -1,493,973 |
Net Acquisitions | -1,750,167 | -3,898,709 | -24,752 | 351,816 | -4,441,059 |
Purchase Of Investment | N/A | N/A | N/A | -5,136 | N/A |
Sale Of Investment | N/A | N/A | 380,903 | N/A | N/A |
Purchase Sale Intangibles | -1,266,290 | -1,136,711 | -1,357,224 | 310,728 | -630,789 |
Other Investing Activity | -849,585 | -5,836,934 | -1,464,482 | 246,528 | -661,433 |
Investing Cash Flow | $-1,984,021 | $-10,850,090 | $-2,443,553 | $2,774,724 | $-6,836,522 |
Cash Flows From Financing Activities | |||||
Change In Short Term Borrowing | -414,219 | 1,262,875 | 437,282 | -4,799,592 | 3,952,006 |
Debt Issued | 277,390 | 1,267,823 | N/A | 4,234,632 | 6,121,458 |
Debt Repayment | -179,122 | -1,971,619 | N/A | N/A | N/A |
Common Stock Issued | 12,439 | 30,923 | 28,877 | 37,236 | 65,122 |
Dividend Paid | -2,795,043 | -4,288,333 | -5,499,025 | -5,106,468 | -5,047,586 |
Other Financing Activity | -3,918,285 | 4,716,301 | -5,402,764 | -7,375,298 | -7,440,496 |
Financing Cash Flow | $-7,016,840 | $1,017,969 | $-10,435,630 | $-13,009,490 | $-2,349,496 |
Exchange Rate Effect | -123,146 | 188,009 | -39,878 | -50,076 | -104,706 |
Beginning Cash Position | 4,260,357 | 4,723,721 | 7,235,776 | 6,203,004 | 5,218,690 |
End Cash Position | 3,555,066 | 4,236,382 | 5,251,507 | 6,756,408 | 6,168,704 |
Net Cash Flow | $-705,291 | $-487,339 | $-1,984,269 | $553,404 | $950,014 |
Free Cash Flow | |||||
Operating Cash Flow | 8,418,715 | 9,156,771 | 10,934,790 | 10,838,240 | 10,240,740 |
Capital Expenditure | -1,634,485 | -1,413,777 | -1,611,617 | -1,574,184 | -1,615,278 |
Free Cash Flow | 6,784,230 | 7,742,994 | 9,323,173 | 9,264,056 | 8,625,462 |